Study of Indoxyl Sulfate Effects on Heart and Blood Vessel Health in Adults with Acute Kidney Injury

What this Trial Is About

Researchers are studying acute kidney injury AKI, a common condition in hospital and intensive care settings, which increases the risk of developing chronic kidney disease and cardiovascular problems. The study aims to understand if high levels of uremic toxins, particularly Indoxyl sulfate IS, during AKI are linked to early changes in blood vessel stiffness and heart function. This investigation focuses on measuring arterial stiffness using pulse wave velocity PWV three months after an AKI episode. Participants will undergo blood sample collections to measure various substances including IS, Para-cresyl Sulfate PCS, Fibroblast Growth Factor 23 FGF-23, and markers related to vascular and cardiac health. The study is non-randomized and uses a double masking approach to assess correlations between these substances and vascular and cardiac outcomes. Measurements and assessments are done in both conventional hospital departments and nephrology intensive care units. During the study, participants will have their pulse wave velocity measured at baseline and again three months after the AKI episode to observe changes. Blood samples will be analyzed for several biomarkers including serum creatinine, IS, PCS, FGF-23, and others linked to heart and vascular function. The main outcome is the change in PWV from baseline after three months. The study also evaluates other cardiovascular and arterial health markers, with participation lasting at least three months.

Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury